Friday, February 28, 2020 4:50:14 PM
Gilead said it would conduct two studies with a total of 1,000 patients across mainly Asian countries, as well as other nations with high numbers of diagnosed patients.
Gilead is kicking off the studies following the U.S. Food and Drug Administration's acceptance of its investigational new-drug application, an early first step for studying unproven drugs in humans.
The studies, if successful, would help contribute to a larger dataset needed to win regulatory approval for the drug. It is too early to say if the two studies alone would be sufficient for regulators, said Diana Brainard, Gilead senior vice president for HIV and emerging viral infections.
"Things are moving so quickly, it's hard for us to gauge what the right approval package would look like in the U.S. or abroad," Dr. Brainard said in an interview. "We're in data-collection mode right now."
Gilead hopes to have at least an initial set of data results in May, Dr. Brainard said.
Gilead's drug, remdesivir, is already being studied in two sets of clinical trials. Chinese researchers earlier in February began enrolling patients with both moderate and severe symptoms of coronavirus.
On Tuesday, the National Institutes of Health announced the start of the first U.S. study of remdesivir, which is being led by researchers at the University of Nebraska.
In both the Chinese and NIH studies, patients are randomly assigned to receive either remdesivir or a placebo; neither patients nor researchers are informed who is receiving the actual drug. The Gilead study, by contrast, won't include the placebo option.
The first of the two Gilead studies will enroll 400 patients with severe symptoms, with half of the subjects receiving remdesivir infusions for five days, and half receiving 10 days of infusions. Patients will be evaluated on whether their fevers normalize and the amount of oxygen in their blood increases.
The second study will enroll 600 patients with moderate symptoms. A third of the subjects will receive five days of remdesivir treatment, a third will receive 10 days of remdesivir and a third will receive only standard treatment and no remdesivir. The study will evaluate the drug's effectiveness by the percentage of patients discharged from the hospital within 14 days of treatment.
Write to Joseph Walker at joseph.walker@wsj.com
Recent GILD News
- Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024 • Business Wire • 05/07/2024 12:30:00 PM
- Gilead Sciences to Present at Upcoming Investor Conferences • Business Wire • 04/30/2024 08:05:00 PM
- FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV • Business Wire • 04/26/2024 12:00:00 PM
- Exxon Mobil Net Profit Drops 28% to $8.22 Billion, Atlassian Surprises with Revenue Boost and Co-CEO Exit, and More in Earnings • IH Market News • 04/26/2024 11:47:51 AM
- Gilead Sciences Announces First Quarter 2024 Financial Results • Business Wire • 04/25/2024 08:02:00 PM
- U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast • IH Market News • 04/25/2024 11:53:54 AM
- Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024 • Business Wire • 04/08/2024 08:05:00 PM
- FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six • Business Wire • 03/28/2024 12:30:00 PM
- Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program • GlobeNewswire Inc. • 03/28/2024 11:00:00 AM
- Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program • Business Wire • 03/28/2024 11:00:00 AM
- Gilead Sciences Announces Completion of Acquisition of CymaBay • Business Wire • 03/22/2024 01:18:00 PM
- Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant • Business Wire • 03/18/2024 11:29:00 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 03/11/2024 12:34:07 PM
- Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer • Business Wire • 03/11/2024 12:24:00 PM
- Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities • Business Wire • 03/06/2024 09:30:00 PM
- Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 • Business Wire • 03/06/2024 03:25:00 PM
- Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers • Business Wire • 03/06/2024 01:00:00 PM
- New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19 • Business Wire • 03/05/2024 09:35:00 PM
- Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health • Business Wire • 03/05/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:35:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/29/2024 09:49:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/28/2024 09:38:50 PM
- Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S. • Business Wire • 02/27/2024 03:00:00 PM
- U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance • Business Wire • 02/26/2024 09:05:00 PM
- Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024 • Business Wire • 02/26/2024 01:30:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM